AR104340A1 - Composición farmaceutica que contiene inhibidor de bromodominio - Google Patents
Composición farmaceutica que contiene inhibidor de bromodominioInfo
- Publication number
- AR104340A1 AR104340A1 ARP160101100A ARP160101100A AR104340A1 AR 104340 A1 AR104340 A1 AR 104340A1 AR P160101100 A ARP160101100 A AR P160101100A AR P160101100 A ARP160101100 A AR P160101100A AR 104340 A1 AR104340 A1 AR 104340A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- pharmaceutical composition
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title abstract 2
- UWZAJPITKGWMFJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Chemical compound Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O UWZAJPITKGWMFJ-UHFFFAOYSA-N 0.000 abstract 4
- 229920000642 polymer Polymers 0.000 abstract 3
- 102000001805 Bromodomains Human genes 0.000 abstract 1
- 108050009021 Bromodomains Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000010922 spray-dried dispersion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104340A1 true AR104340A1 (es) | 2017-07-12 |
Family
ID=57143581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101100A AR104340A1 (es) | 2015-04-22 | 2016-04-21 | Composición farmaceutica que contiene inhibidor de bromodominio |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (enExample) |
| EP (1) | EP3285770A4 (enExample) |
| JP (1) | JP2018513863A (enExample) |
| KR (1) | KR20170139119A (enExample) |
| CN (1) | CN107613981A (enExample) |
| AR (1) | AR104340A1 (enExample) |
| AU (1) | AU2016252992A1 (enExample) |
| BR (1) | BR112017022691A2 (enExample) |
| CA (1) | CA2983446C (enExample) |
| CL (1) | CL2017002679A1 (enExample) |
| CO (1) | CO2017011482A2 (enExample) |
| EA (1) | EA201792317A1 (enExample) |
| EC (1) | ECSP17071545A (enExample) |
| HK (1) | HK1243948A1 (enExample) |
| IL (1) | IL255120B (enExample) |
| MX (2) | MX390077B (enExample) |
| PE (1) | PE20180036A1 (enExample) |
| PH (1) | PH12017501933A1 (enExample) |
| SG (1) | SG11201708627TA (enExample) |
| TW (1) | TW201642860A (enExample) |
| WO (1) | WO2016172618A1 (enExample) |
| ZA (1) | ZA201707186B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3528810A4 (en) * | 2016-10-20 | 2020-06-17 | Celgene Quanticel Research, Inc. | BROMDOMAIN INHIBITOR |
| PL3532059T3 (pl) | 2016-10-27 | 2022-05-09 | Celgene Quanticel Research, Inc. | Terapia skojarzona z zastosowaniem inhibitora białka bet |
| EA202190170A1 (ru) * | 2018-07-23 | 2021-08-13 | Селджен Квонтисел Рисёрч, Инк. | Способ получения ингибитора бромодомена |
| JP2024507232A (ja) * | 2021-02-22 | 2024-02-16 | セルジーン・クオンティセル・リサーチ・インコーポレイテッド | 前立腺がんの治療に用いるブロモドメイン（ｂｅｔ）阻害剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| DK3290407T3 (da) * | 2013-10-18 | 2020-03-23 | Celgene Quanticel Res Inc | Bromodomæneinhibitorer |
| EP3528810A4 (en) * | 2016-10-20 | 2020-06-17 | Celgene Quanticel Research, Inc. | BROMDOMAIN INHIBITOR |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016252992A1 (en) | 2017-11-09 |
| MX2020010899A (es) | 2022-02-15 |
| BR112017022691A2 (pt) | 2018-07-17 |
| MX377159B (es) | 2025-03-07 |
| CL2017002679A1 (es) | 2018-05-25 |
| IL255120A0 (en) | 2017-12-31 |
| TW201642860A (zh) | 2016-12-16 |
| EA201792317A1 (ru) | 2018-03-30 |
| MX2017013501A (es) | 2018-02-09 |
| CA2983446A1 (en) | 2016-10-27 |
| EP3285770A4 (en) | 2018-10-31 |
| HK1243948A1 (zh) | 2018-07-27 |
| PE20180036A1 (es) | 2018-01-09 |
| ZA201707186B (en) | 2019-01-30 |
| KR20170139119A (ko) | 2017-12-18 |
| CA2983446C (en) | 2024-04-09 |
| SG11201708627TA (en) | 2017-11-29 |
| ECSP17071545A (es) | 2017-12-01 |
| CN107613981A (zh) | 2018-01-19 |
| EP3285770A1 (en) | 2018-02-28 |
| US20160310423A1 (en) | 2016-10-27 |
| CO2017011482A2 (es) | 2018-01-31 |
| WO2016172618A1 (en) | 2016-10-27 |
| JP2018513863A (ja) | 2018-05-31 |
| IL255120B (en) | 2021-03-25 |
| PH12017501933A1 (en) | 2018-03-19 |
| NZ736630A (en) | 2024-03-22 |
| MX390077B (es) | 2025-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017011482A2 (es) | Inhibidores de bromodominio | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| CL2018003135A1 (es) | Derivados aromáticos de sulfonamida. | |
| CY1123295T1 (el) | Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης | |
| MX2018000412A (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CL2016001963A1 (es) | Heteroarilos inhibidores de syk | |
| MX2017008698A (es) | Composiciones multi-suplementos. | |
| CU20170089A7 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CO2017005038A2 (es) | Composicones y métodos de tratamiento con profármacos de tizoxanida, un análogo o sal de la misma | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| CL2017002334A1 (es) | Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular | |
| CL2017000178A1 (es) | Compuestos para usar en el tratamiento antihelmíntico | |
| MX2016014859A (es) | Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas. | |
| MX374654B (es) | Compuestos útiles para inhibir ror-gamma-t. | |
| DK3478310T3 (da) | Sammensætninger, som er anvendelige inden for forebyggelsen og/eller behandlingen af osteoartikulær inflammation og smerte samt bruskskade | |
| CL2018001157A1 (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |